A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

September 30, 2026

Conditions
Respiratory Syncytial VirusHuman Metapneumovirus
Interventions
BIOLOGICAL

mRNA-1345

Sterile liquid for injection

BIOLOGICAL

mRNA-1365

Sterile liquid for injection

BIOLOGICAL

Placebo

0.9% sodium chloride (normal saline) solution for injection

DRUG

Nimenrix

Solution for injection

Trial Locations (58)

2001

Shandukani Research CRS, Hillbrow

2013

Wits Health Consortium, Johannesburg

6009

Telethon Kids Institute, Nedlands

7440

Family Centre for Research with Ubuntu (FAMCRU)- Tygerberg, Cape Town

7530

Practice Dr Jan Vermeulen, Cape Town

15706

Complexo Hospitalario Universitario De Santiago, Santiago de Compostela

20016

Meridian Clinical Research, Washington D.C.

25198

Hospital Universitario Arnau de Vilanova, Lleida

27703

Duke Vaccine and Trials Unit, Durham

28041

Hospital Universitario 12 de Octubre, Madrid

28046

Hospital Carlos III-Hospital Universitario La Paz, Madrid

32209

University Of Florida Health Science Center, Jacksonville

37232

Vanderbilt Vaccine Research Program, Nashville

44121

Senders Pediatrics, South Euclid

63110

Washington University School of Medicine in St. Louis, St Louis

70508

MedPharmics - Platinum - PPDS, Lafayette

75024

Village Pediatrics, Plano

77054

Mercury Clinical Research, Inc., Houston

77065

CyFair, Houston

77087

Pediatric Associates, Houston

77375

North Houston Internal Medicine &amp; Pediatric Clinic, Tomball

77469

Pediatric Center, Richmond

79905

Texas Tech University Health Sciences Center, El Paso

80110

Velocity Clinical Research, Denver, Englewood

83404

Clinical Research Prime, Idaho Falls

90057

Matrix Clinical Research, Los Angeles

90095

Los Angeles Children's Hospital, Los Angeles

98105

Childrens Hospital Regional Medical Center, Seattle

20016-4358

Meridian Clinical Research, Washington D.C.

32829-8070

Accel Research Sites - Nona Pediatric Center, Orlando

01655-0002

Umass Memorial Medical Center, Worcester

01655

UMASS Chan Medical School, Worcester

48202-2608

Henry Ford Health System, Detroit

48075-5400

Great Lakes Research Institute, Southfield

55454-1404

Pediatric Specialty Care Discovery Clinic, Minneapolis

68901-2640

Meridian Clinical Research, Hastings

02886

Velocity Clinical Research - Providence, Providence

29406-9170

Palmetto Pediatrics, PA, North Charleston

77469-3348

Mercury Clinical Research, Inc., Richmond

V5Z 4H4

BC Children's Hospital - Vaccine Evaluation Centre - Neonatology, Vancouver

B3K 6R8

Dalhousie University IWK Health Centre, Halifax

N6A 5W9

London Health Sciences Centre - Victoria Hospital, London

Unknown

Universite de Montreal - Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montreal

CEVAXIN Chorrera, La Chorrera

CEVAXIN 24 de Diciembre, Panama City

Imperial College London and Imperial College Healthcare NHS, London

0401

CEVAXIN David, David

0801

CEVAXIN Avenida Mexico, Panama City

30-389

Centrum Badań Klinicznych JCI Jagiellońskie Centrum Innowacji Sp. z o.o., Krakow

55-100

Szpital im. Sw. Jadwigi Slaskiej w Trzebnicy, Trzebnica

53-149

Vistamed, Wroclaw

30-349

Centrum Medyczne Plejady, Krakow

0152

Setshaba Research centre, Soshanguve

L12 2AP

Alder Hey NHS Foundation Trust - Pharmacy Clinical Trials, Liverpool

SW170RE

St George's Hospital, London

NR4 7UY

Norfolk and Norwich University Hospitals, Norwich

OX3 9DU

John Radcliffe Hospital, Oxford

SO16 6YD

Southampton General Hospital, Southampton

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY